Medication info
Olmesartan Medoxomil and Rosuvastatin Tablet 20/10 mg

Olmesartan Medoxomil and Rosuvastatin Tablet 20/10 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
White or yellowish round film-coated tablets
Packaging
30 tablets/box [(10 tablets/Alu-Alu) × 3]
Approval status
Active

MFDS item code 202003964 · Approved 2020.05.28 · Insurance code 657807380

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced effective circulating blood volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while monitoring their condition closely. 2. Older adults No dose adjustment is necessary when this medicine is administered to older adults aged 65 years or older. No overall differences in efficacy or safety were observed between older and younger patients; however, the possibility of a more sensitive response in some older adults cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which provides control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20mg daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of a 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of a 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take Olmesartan Medoxomil and Rosuvastatin together. Olmesartan Medoxomil helps effectively treat hypertension, especially essential hypertension. Rosuvastatin is mainly used as an adjunct treatment for lipid disorders such as hypercholesterolemia that are not improved by diet and exercise. Additionally, Rosuvastatin has a positive effect in slowing the progression of atherosclerosis and reducing the risk of cardiovascular diseases. It particularly helps decrease the risk of stroke, myocardial infarction, and revascularization procedures. Therefore, this medication is used for managing hypertension and hyperlipidemia, and for reducing cardiovascular disease risk.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase the dose to 20mg once daily. If additional blood pressure reduction is required, the dose may be increased to a maximum of 40mg once daily. The blood pressure-lowering effect occurs within 2 weeks after starting treatment and reaches its maximum effect at approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). For patients who may have reduced effective circulating blood volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a lower dose while monitoring their condition closely. 2. Older adults No dose adjustment is necessary when this medicine is administered to older adults aged 65 years or older. No overall differences in efficacy or safety were observed between older and younger patients; however, the possibility of a more sensitive response in some older adults cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is necessary for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, which may be increased to a maximum of 20mg daily. Use of this medicine is not recommended in patients with severe hepatic impairment because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10mg once daily, which provides control in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20mg daily. 2. Older adults No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5mg. Administration of a 40mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5mg. Administration of a 40mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in children under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if administered to pregnant women in the second and third trimesters; therefore, it should be discontinued immediately if pregnancy is confirmed. This medication should not be administered to specific patients, including those with an allergy to this medication or its components, pregnant women or women of childbearing potential, nursing mothers, patients with severely impaired renal function, those with severe liver disease, bile duct obstruction, or muscle disorders. In patients with low blood pressure or low salt levels, hypotension may occur upon the initial administration of this medication, thus careful observation is required during administration. Patients with impaired kidney function, kidney transplant recipients, those with renovascular hypertension, or patients at risk of hyperkalemia should undergo regular monitoring of kidney function and serum potassium levels when receiving this medication. This medication may affect liver function, thus patients with a history of liver disease or elevated liver enzyme levels should undergo periodic liver function tests. Muscle pain or myopathy may occur, and rarely rhabdomyolysis may occur; therefore, if symptoms such as muscle pain, weakness, or cramps arise, consultation with a physician should be sought immediately. Caution should be exercised when this medication is used by patients who consume excessive alcohol or have a history of liver disease. Dizziness may occur due to blood pressure-lowering effects; thus, caution is advised during high-altitude work or when operating dangerous machinery, including driving. This medication may interact with other drugs, especially potassium-sparing diuretics, potassium supplements, lithium, non-steroidal anti-inflammatory drugs, other antihypertensives, certain antibiotics, and antifungals; hence, inform your physician or pharmacist when taking these medications together. Women who are pregnant or breastfeeding should not use this medication, and women of childbearing potential should employ suitable contraceptive methods. Safety and efficacy in children under 18 years have not been established; therefore, avoid use in this age group. Elderly patients may have different metabolic rates and thus dosage adjustments and careful observation are necessary during administration. In the case of overdose, hypotension or heart abnormalities may occur, and immediate medical assistance should be sought; there is no specific antidote for this medication. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Increased ALT, Increased AST, Elevated serum creatinine, Decreased creatinine clearance, Headache, Dizziness, Impaired perception, Neuromuscular disease, Drowsiness, Gastroesophageal reflux disease, Constipation, Dental caries, Dyspepsia, Gastric ulcer, Gastritis, Gastroenteritis, Musculoskeletal rigidity, Atrial fibrillation, Hypoglycemia, Chest pain, Tooth extraction, Chest discomfort, Peripheral edema, Dizziness, Abdominal pain, Nausea, Palpitations, Hypercholesterolemia, Dyslipidemia, Hyperuricemia, Arthralgia, Arthritis, Myalgia, Rash, Facial edema, Asthenia, Angioedema, Anaphylactic reaction, Vomiting, Chronic malabsorption syndrome-like intestinal disease, Intestinal vascular edema, Rhabdomyolysis, Hyperkalemia, Acute renal failure, Hair loss, Pruritus, Urticaria, Autoimmune hepatitis, Dizziness including positional dizziness, Palpitations, Increased blood pressure, Back pain, Increased serum creatinine, Diarrhea, Cough, Epistaxis, Upper respiratory tract infection, Asthma, Hypersensitivity reaction including angioedema, Diabetes, Constipation, Nausea, Abdominal pain, Pancreatitis, Pruritus, Rash and urticaria, Myalgia, Myopathy including myositis, Rhabdomyolysis, Asthenia, Polyneuropathy, Amnesia, Peripheral neuropathy, Dyspnea, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Increased transaminases, Stevens-Johnson syndrome, Eosinophilia with systemic symptoms drug reaction syndrome, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disturbances including insomnia and nightmares, Interstitial lung disease, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Cognitive impairment, Severe muscle weakness, Ocular myasthenia.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to keep it at a cool room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/box [(10 tablets/Alu-Alu) × 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.